… value of neoadjuvantchemotherapy for pancreatic cancer. … Neoadjuvantchemotherapy for primary resectable … Association of modifiedFOLFIRINOX-regimen-based neoadjuvanttherapy …
… Total neoadjuvanttherapy with FOLFIRINOX in combination … of first line FOLFIRINOX versus gemcitabine/nabpaclitaxel … with FOLFIRINOX in patients with borderline resectable and …
… for neoadjuvanttherapy followed by surgery. It is difficult to evaluate the resectability of tumors after neoadjuvanttherapy … Gemcitabine/nab-paclitaxel versus FOLFIRINOX in locally …
… neoadjuvanttherapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable … versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic …
… treatment efficacy of neoadjuvantgemcitabine/nab-paclitaxel … (pts)who received neoadjuvant treatment for BRPC at our … ), or 4 cycles of FOLFIRINOX or 2 cycles of gemcitabine plus nab-…
… neoadjuvanttherapy in pancreatic cancer, and many international guidelines have recognized neoadjuvanttherapy … 康剂量的方式在国内率先对FOLFIRINOX 方案进行 了成功改良[30],并…
… value of preoperative neoadjuvantchemotherapy (NAC) and … ,NCCN指南优先推荐以 FOLFIRINOX或吉西他滨为基础的化疗… patients with small borderline-resectable pancreatic cancer …
… Locally advanced pancreatic cancer: neoadjuvanttherapy with folfirinox results in resectability … FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for neoadjuvanttreatment of resectable …